Form 8-K - Current report:
SEC Accession No. 0001493152-25-011083
Filing Date
2025-03-21
Accepted
2025-03-21 08:15:12
Documents
15
Period of Report
2025-03-21
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 46860
2 ex99-1.htm EX-99.1 152785
  Complete submission text file 0001493152-25-011083.txt   447643

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bfri-20250321.xsd EX-101.SCH 3976
4 XBRL DEFINITION FILE bfri-20250321_def.xml EX-101.DEF 30397
5 XBRL LABEL FILE bfri-20250321_lab.xml EX-101.LAB 37210
6 XBRL PRESENTATION FILE bfri-20250321_pre.xml EX-101.PRE 27416
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6647
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 25758588
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)